Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Phosphorus or phosphorus compound
Patent
1987-08-03
1990-03-27
Robinson, Douglas W.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Phosphorus or phosphorus compound
424673, 424676, 514389, A61K 3342, A61K 3314, A61K 31415
Patent
active
049119311
ABSTRACT:
A pharmaceutical composition for increasing bone mass and preventing loss of bone mass is provided, comprising a fluoride source and a mitogenic hydantoin in combination with a pharmaceutically acceptable carrier. The combination is administered to a vertebrate, typically in the form of an orally administratable tablet or capsule.
REFERENCES:
patent: 4386100 (1983-05-01), Brittain et al.
patent: 4501754 (1985-02-01), Wechter et al.
patent: 4686104 (1987-08-01), Bockman et al.
patent: 4726952 (1988-02-01), Walsdorf et al.
Melsen, F. et al., (1985), "A Quantitative Analysis of Bone Changes Following Anticonvulsant Therapy", Universal Institute of Pathology, pp. 247-251.
Harris, M. et al., (1978), "Anticonvulsant Osteomalacia Induced in the Rat by Diphenylhydantoin", Caleif. Tiss. Res. 25, 13-17.
Wolschendorf, K. et al., "A Quantitative Determination of Anticonvulsant-Induced Bone Demineralization by an Improved X-ray Densitometry Technique", Neuroradiology 25:315-318, (1983).
Richens, A. et al., (1970), "Disturbance of Calcium Metabolism by Anticonvulsant Drugs", British Med. Jour. 4:73-76.
Johnell, O. et al., (1979), "Bone Morphology in Epileptics", Calcif. Tissue Int. 28:93-97.
Mosekilde, L. et al., (1976), "Anticonvulsant Osteomalacia Determined by Quantitative Analysis of Bone Changes", Acta med. scand. 199:349-355.
Israel, H., (1974), "Abnormalities of Bone and Orofacial Changes from Anticonvulsant Drugs", 34:104-105.
Lidgren, Lars et al., (1979), "Bone Mineral Content in Epileptics", Calcif. Tissue Int. 28:99-102.
Tjellesen, L. et al., (1985), "Different Actions of Vitamin D.sub.2 and D.sub.3 on Bone Metabolism in Patients Treated with Phenobarbitone/Phenytoin", Calc. Tiss. Int. 37:218-222.
Christiansen et al., (1973), "Incidence of Anticonvulsant Osteomalacia and Effect of Vitamin D: Controlled Therapeutic Trial", Brit. Med. J. 4:695-701.
Calkin et al., (1986), "Osteoporosis", The Practice of Geriatrics, pp. 466-476.
Krane, S., (1988), "Disorders of Bone Formation and Bone Resorption", Scientific American Section, Rheumatology, Chapter 11, p. 3.
Aurbach et al., (1981), Textbook of Endocrinology, 6th ed., Chapter 19.
Chem. Abstracts, 89(9):71112m, "Assessment of Calcium-Phosphate Metabolism Disturbances in Patients on Long-term Treatment w/Diphenylnydantoin", Pupek-Musialik, 1978.
Chem. Abstracts, 85(19):137564m, "Osteomalacia in Epileptic Patients treated with Anticonvulsants", Christiansen et al., 1974.
Chem. Abstracts, 73(11):54302a, "The Osteogenic Hypertrophic and the Teratogenic Effects of Sodium Diphenylydantoin", Baratieri et al., 1969.
Journal of Med. Chem., 1981, 24(7), 843-7, Henderson et al.
Compendium of Drug Therapy, (1983/1984), Biomed. Information Inc., pp. 15:5-7.
Henley III Raymond J.
Neeley Richard L.
Robinson Douglas W.
LandOfFree
Pharmaceutical combination for treatment of bone-wasting disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical combination for treatment of bone-wasting disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical combination for treatment of bone-wasting disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1649853